PD-L1

:   programmed death ligand 1

PD-1

:   programmed death 1

LAG-3

:   lymphocyte activation gene 3

CTLA-4

:   cytotoxic T-lymphocyte-associated protein 4

PD-L2

:   programmed death ligand 2

IDO

:   indoleamine 2, 3-dioxygenase

VISTA

:   V-domain Ig suppressor of T cell activation

HR

:   hazard ratio

M/F

:   male/female

NA

:   not available

HNC

:   head and neck cancer

HNSCC

:   head and neck squamous cell carcinoma

OSCC

:   oral squamous cell carcinoma

NPC

:   nasopharyngeal carcinoma

OPSCC

:   oropharyngeal squamous cell carcinoma

LSCC

:   laryngeal squamous cell carcinoma

cut-off value

:   the value that can be diagnosed as positive/high expression of an immune checkpoint molecule

AQUA

:   automated quantitative analysis

IHC

:   immunohistochemistry

IF

:   immunofluorescence

qRT-PCR

:   quantitative reverse transcription polymerase chain reaction

FACS

:   fluorescence-activated cell sorting

FISH

:   fluorescence in situ hybridization

OS

:   overall survival

PFS

:   progression-free survival

DFS

:   disease-free survival

DSS

:   disease-specific survival

DMFS

:   distant metastases-free survival

P

:   prospective

NOS

:   Newcastle--Ottawa Quality Assessment Scale

CI

:   confidence interval

Introduction
============

Head and neck cancer (HNC) is the sixth most common malignancy worldwide \[[@r1]\]. Most patients exhibit advanced-stage disease, including regional lymph node involvement, and 10% of patients have distant metastases \[[@r2]\]. The traditional treatment options for HNC are surgery, radiotherapy and chemotherapy \[[@r3]\], which have severe adverse effects. Furthermore, some patients do not benefit much from these treatments, and are likely to relapse. Anatomic complexities often lead to malfunctions in speaking, swallowing and breathing after treatments, hampering patients' long-term quality of life \[[@r4]\]. Although there have been certain advances in treatment, the overall survival of HNC patients is still unsatisfactory, and the five-year survival rate is less than 50% \[[@r5]--[@r7]\].

Immunosuppressive patients are prone to suffer from HNC \[[@r8]\], although the predominant causes of HNC are tobacco and alcohol consumption \[[@r4]\] and viral infections \[[@r9],[@r10]\]. Among the functions of the immune cells, immune checkpoint activity has been reported to be involved in the surveillance of tumor development and progression \[[@r11]\]. Immune checkpoint molecules including programmed death 1 (PD-1) \[[@r12],[@r13]\], indoleamine 2, 3-dioxygenase (IDO) \[[@r14],[@r15]\], B7-H3 \[[@r16],[@r17]\], lymphocyte activation gene 3 (LAG-3) \[[@r18]\], cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) \[[@r19]\], programmed death ligand 2 (PD-L2) \[[@r20]\], V-domain Ig suppressor of T cell activation (VISTA) \[[@r21]\], B7-H4 \[[@r22]\] and programmed death ligand 1 (PD-L1) \[[@r23]--[@r25]\] have been used as markers to evaluate the prognosis of HNC. However, the survival rates of patients with high expression of immune checkpoint molecules have differed according to the overexpressed molecule.

In the present study, we performed a systematic review of the available literature on this topic in PubMed, Embase and the Cochrane Library. Then, we conducted a meta-analysis of the survival rates (including overall survival \[OS\], disease-free survival \[DFS\], progression-free survival \[PFS\], disease-specific survival \[DSS\] and distant metastases-free survival \[DMFS\]) of patients expressing different levels of immune checkpoint molecules.

RESULTS
=======

Study characteristics
---------------------

The characteristics of the included studies are shown in [Table 1](#t1){ref-type="table"}. There were 52 prospective studies comparing contemporary series of patients (level of evidence: 3b) in 51 articles. These studies included 7127 patients and met the criteria for meta-analysis. The literature selection procedure is presented in [Figure 1](#f1){ref-type="fig"}. The included articles were evaluated by the Newcastle--Ottawa Scale (NOS; [Supplementary Table 1](#SD1){ref-type="supplementary-material"}), and all the articles were published between 2010 and 2018. Roughly half of the studies were conducted in Asia (n=23), while the remainder were conducted in Europe (n=18), North and South America (n=6), Oceania (n=4) and Africa (n=1). Thus, the samples included in this meta-analysis covered most of the continents of the world. In terms of the immune checkpoint molecules, the majority of the studies evaluated PD-L1 (n=40), while the rest assessed PD-1 (n=8) and IDO (n=4). The sample sizes of the included studies ranged from 38 to 517. With reference to the mean value of all the samples, 17 studies were considered to have a large sample size (n \> 139), while 35 had a small sample size (n ≤ 139). Forty-three studies explored the prognostic value of their chosen immune checkpoint molecule for OS, 19 for DFS, 6 for PFS, 5 for DSS and 3 for DMFS.

###### Characteristics of included studies.

  ---------------------------------------- ------------ ------------- ----------- ---------------- ------------- ----------------------- ---------------------------------- ------------------ ----------- ------------- --------------- -------------- -----------
  Author and year                          Target       Country /\    Ethnicity   Tumor location   Sample size   Gender M/F              Cut-off value                      Detection method   TNM stage   Outcome       HR estimation   Study design   NOS score
                                                        Region                                                                                                                                                                                          

  Ahn et al. 2017 \[[@r23]\]               PD-L1        Korea         Asian       OSCC             68            45/23                   Grade \> 1                         IHC                I-IV        OS DFS        reported        P              7

  Badoual et al. 2013 \[[@r12]\]           PD-1         France        Caucasian   HNSCC            64            NA                      \> median                          IF                 I-IV        OS            reported        P              6

  Balempas et al. 2017 \[[@r36]\]          PD-L1        Germany       Caucasian   HNSCC            161           131/30                  \> 5%                              IHC                I-IV        OS DMFS       reported        P              7

  Ben-Haj-Ayed et al. 2016 \[[@r14]\]      IDO          Tunisia       Caucasian   NPC              71            48/23                   \> median                          IHC                I-IV        OS DFS        reported        P              7

  Birtalan et al. 2017 \[[@r24]\]          PD-L1        Hungary       Caucasian   HNSCC            106           90/16                   Score \> 0%                        IHC                I-IV        DSS           reported        P              6

  Budczies et al. 2016 \[[@r25]\]          PD-L1        Germany       Caucasian   HNSCC            517           NA                      \> median                          qRT-PCR            NA          OS DFS        reported        P              5

  Chan et al. 2017 \[[@r46]\]              PD-L1        USA           Caucasian   NPC              161           117/44                  ≥ 1%                               IHC                I-IV        OS PFS        reported        P              6

  Chang et al. 2017 \[[@r47]\]             PD-L1        Philippines   Asian       NPC              56            43/13                   \> 1%                              IHC                I-IV        OS            reported        P              5

  Chen et al. 2015 \[[@r48]\]              PD-L1        Taiwan        Asian       OSCC             218           145/73                  \> 5%                              IHC                I-IV        OS            reported        P              7

  Chen et al. 2017 \[[@r49]\]              PD-L1        China         Asian       HNSCC            496           NA                      \> 5%                              qRT-PCR            I-IV        OS            reported        P              7

  Cho et al. 2011 \[[@r50]\]               PD-L1        Korea         Asian       OSCC             45            32/13                   Grade \> 1                         IHC                I-IV        OS            estimated       P              6

  De Meulenaere et al. 2017 \[[@r51]\]     PD-L1        Belgium       Caucasian   OSCC             99            82/17                   \> 1%                              IHC                I-IV        OS DFS        reported        P              6

  Fang et al. 2014 \[[@r52]\]              PD-L1        China         Asian       NPC              139           113/26                  \> 35%                             IHC                I-IV        DFS           estimated       P              6

  Feng et al. 2017 \[[@r53]\]              PD-L1        USA           Caucasian   OSCC             119           74/45                   \< 30 μm                           IHC                I-IV        OS            estimated       P              6

  Fiedler et al. 2018 \[[@r54]\]           PD-L1        Germany       Caucasian   HNSCC            82            73/9                    \> 5%                              IHC                I-IV        OS            reported        P              7

  Hanna et al. 2018 \[[@r37]\]             PD-L1        USA           Caucasian   OSCC             81            49/32                   \> 10%                             IHC                I-IV        OS            reported        P              7

  Hong et al. 2016 \[[@r55]\]              PD-L1        Australia     Caucasian   OSCC             99            79/20                   \> 25%                             IHC                I-IV        OS            reported        P              6

  Hsu et al. 2010 \[[@r13]\]               PD-1         Taiwan        Asian       NPC              46            39/7                    \> median                          IHC                NA          OS DFS        reported        P              4

  Kansy et al. 2017 \[[@r56]\]             PD-1         Germany       Caucasian   HNSCC            56            NA                      NA                                 FACS               I-IV        DFS           reported        P              6

  Kim et al. 2016 \[[@r57]\]               PD-1         Korea         Asian       HNSCC            402           302/100                 \> 5%                              IHC                I-IV        OS DFS        reported        P              6

  Kim et al. 2016 \[[@r58]\]               PD-1         Korea         Asian       OSCC             133           120/13                  \> 5%                              IHC                I-IV        OS            reported        P              7

  Kogashiwa et al. 2017 \[[@r35]\]         PD-L1        Japan         Asian       OSCC             84            57/27                   \> 5%                              IHC                I-IV        OS PFS        reported        P              7

  Laimer et al. 2011 \[[@r15]\]            IDO          Austria       Caucasian   OSCC             88            67/21                   \> 4                               IHC                I-IV        OS            reported        P              7

  Larbcharoensub et al. 2018 \[[@r59]\]    PD-L1        Thailand      Asian       NPC              114           77/67                   ≥ 5%                               IHC                I-IV        OS            estimated       P              7

  Lee et al. 2016 \[[@r60]\]               PD-L1        Hong Kong     Asian       NPC              104           85/19                   \> 1                               IHC                I-IV        PFS DMFS OS   reported        P              5

  Li et al. 2017 \[[@r61]\]                PD-L1        China         Asian       NPC              62            40/14                   \> 20%                             IHC                I-IV        DFS           reported        P              5

  Lin et al. 2015 \[[@r30]\]               PD-L1        Taiwan        Asian       OSCC             305           236/69                  \> 1                               IHC                I-IV        OS            reported        P              6

  Muller et al. 2017 \[[@r62]\]            PD-L1        Germany       Caucasian   HNSCC            293           82/16 142/53 (224/69)   Score ≥ 1                          IHC                I-IV        OS            reported        P              6

  Ock et al. 2016 \[[@r63]\]               PD-L1        South Korea   Asian       HNSCC            141           40/10 61/30 (101/40)    ≥ 5%                               IHC                I-IV        OS            reported        P              6

  Oguejiofor et al. 2017 \[[@r64]\]        PD-L1        UK            Caucasian   OPSCC            124           NA                      \> 5%                              IHC                I-IV        OS            reported        P              7

  Oliveira-Costa et al. 2015 \[[@r65]\]    PD-L1        Brazil        Caucasian   OSCC             142           125/17                  ≥ 5%                               IHC                I-III       DSS           reported        P              6

  Ono et al. 2017 \[[@r66]\]               PD-L1        Japan         Asian       HPSCC            83            79/4                    ≥ 1%                               IHC                III-IV      OS PFS        reported        P              6

  Ono et al. 2018 \[[@r67]\]               PD-L1        Japan         Asian       NPC              66            54/12                   ≥ 5%                               IHC                I-IV        OS PFS        reported        P              7

  Ou et al. 2017 \[[@r68]\]                PD-L1        France        Caucasian   HNSCC            38            NA                      ≥ 1%                               IHC                III-IV      OS PFS        estimated       P              7

  Qu et al. 2018 \[[@r69]\]                PD-L1        China         Asian       NPC              96            72/24                   \> 10%                             IHC                I-IV        DMFS          estimated       P              6

  Riobello et al. 2018 \[[@r70]\]          PD-L1        Spain         Caucasian   SSCC             53            37/16                   ≥ 5%                               IHC                I-IV        OS DFS DSS    reported        P              5

  Roper et al. 2017 \[[@r71]\]             PD-L1        Australia     Caucasian   HNSCC            74            64/10                   \> 5%                              IHC                NA          DFS           reported        P              6

  Satgunaseelan et al. 2016 \[[@r72]\]     PD-L1        Australia     Caucasian   OSCC             217           130/87                  Score ≥ 1                          IHC                NA          DSS           estimated       P              6

  Schneider et al. 2018 \[[@r73]\]         PD-1 PD-L1   Austria       Caucasian   HNSCC            129           97/28                   \> 5%                              IHC                I-IV        OS DFS        reported        P              7

  Seppälä et al. 2016 \[[@r74]\]           IDO          Finland       Caucasian   OSCC             58            29/29                   \> 0                               IHC                I-III       OS            reported        P              6

  Solomon et al. 2018 \[[@r75]\]           PD-L1        Australia     Caucasian   OSCC             190           157/33                  ≥ 5%                               IHC                I-IV        OS            reported        P              7

  Steuer et al. 2018 \[[@r76]\]            PD-1         USA           Caucasian   OPSCC            97            81/16                   Score \> 1                         IHC                I-IV        OS            reported        P              7

  Strati et al. 2017 \[[@r77]\]            PD-L1        Greece        Caucasian   HNSCC            113           75/19                   NA                                 qRT-PCR            I-IV        OS PFS        reported        P              5

  Straub et al. 2016 \[[@r78]\]            PD-L1        Germany       Caucasian   OSCC             80            54/26                   \> 5%                              IHC FISH           I-IV        OS DFS        estimated       P              7

  Tang et al. 2017 \[[@r79]\]              PD-1         China         Asian       NPC              96            NA                      NA                                 IHC                NA          OS            estimated       P              6

  Ukpo et al. 2013 \[[@r80]\]              PD-L1        USA           Caucasian   OPSCC            181           162/19                  \> 5%                              IHC                I-IV        OS DFS DSS    reported        P              7

  Vassilakopoulou et al. 2016 \[[@r81]\]   PD-L1        Greece        Caucasian   LSCC             260           249/11                  \> 59th percentile of AQUA score   IHC                I-IV        OS DFS        reported        P              7

  Ye et al. 2013 \[[@r82]\]                IDO          China         Asian       LSCC             187           179/8                   NA                                 IHC                I-IV        OS DFS        reported        P              6

  Zhang et al. 2015 \[[@r83]\]             PD-1 PD-L1   China         Asian       NPC              139           113/26                  H-score PD-1 \> 0 PD-L1 \> 35      IHC                I-IV        DFS           estimated       P              7

  Zheng et al. 2017 \[[@r84]\]             PD-L1        China         Asian       NPC              85            63/22                   Score \> 2                         IHC                I-IV        OS            estimated       P              6

  Zhu et al. 2017 \[[@r38]\]               PD-L1        China         Asian       NPC              209           150/59                  ≥ 5%                               IHC                I-IV        OS DFS        reported        P              7
  ---------------------------------------- ------------ ------------- ----------- ---------------- ------------- ----------------------- ---------------------------------- ------------------ ----------- ------------- --------------- -------------- -----------

PD-L1: programmed death ligand 1; PD-1: programmed death 1; IDO: indoleamine 2, 3-dioxygenase; M/F: male/female; NA: not available; OSCC: oral squamous cell carcinoma; HNSCC: head and neck squamous cell carcinoma; NPC: nasopharyngeal carcinoma; OPSCC: oropharyngeal squamous cell carcinoma; HPSCC: hypopharyngeal squamous cell carcinoma; SSCC: sinonasal squamous cell carcinoma; LSCC: laryngeal squamous cell carcinoma; cut-off value: the value that can be diagnosed as positive/high expression of an immune checkpoint molecule; AQUA: automated quantitative analysis; IHC: immunohistochemistry; IF: immunofluorescence; qRT-PCR: quantitative reverse transcription polymerase chain reaction; FACS: fluorescence-activated cell sorting; FISH: fluorescence in situ hybridization; OS: overall survival; DFS: disease-free survival; DMFS: distant metastases-free survival; DSS: disease-specific survival; PFS: progression-free survival; P: prospective; NOS: Newcastle--Ottawa Quality Assessment Scale.
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Methodological quality of the included studies
----------------------------------------------

The quality of the included studies was generally high. Most of the studies mentioned the length of the follow-up period, and the majority provided adequate follow-up data for more than five years. Nevertheless, almost none of the prospective studies had an exposed cohort that sufficiently represented the general characteristics of the population in the community, as this factor was not considered in the study design. None of the studies were designed with adequate comparability of cohorts, due to their failure to match exposed and non-exposed individuals and/or adjust for confounders. Methods for handling missing data and intention-to-treat analysis were not adequately described in the majority of the studies.

Immune checkpoint molecule expression and prognosis of HNC patients
-------------------------------------------------------------------

Forty-three studies with 6225 patients reported the relationship between OS and at least one of the three immune checkpoint molecules in HNC. The expression of these molecules was detected mainly at the protein level, except for three studies that evaluated *PD-L1* mRNA levels. Overexpression was defined based on cut-off criteria that differed among the studies (as presented in [Table 1](#t1){ref-type="table"}). When the data for all three immune checkpoint molecules were pooled, there was no significant relationship between the overexpression of these molecules and OS (hazard ratio \[HR\] = 0.964; 95% confidence interval \[CI\]: 0.791-1.175, *P* = 0.714; [Table 2](#t2){ref-type="table"}), and there was obvious overall heterogeneity (I^2^ = 74.8%, *P*~h~ \< 0.001; [Figure 2](#f2){ref-type="fig"}). Similar results were obtained for DFS, PFS, DSS and DMFS.

###### Results of the meta-analysis on the prognostic effects of immune checkpoint molecules in HNC patients.

  -------------------------------------------- --------------- --------------- --------------------- --------------------- --------------- ------------------- ---------
                                               **Variable**    **Study no.**   **Sample size**       **HR (95% CI)**       ***P* value**   **Heterogeneity**   
  **I^2^**                                     ***P* value**                                                                                                   
  OS                                           Overall         43              6225                  0.964 (0.791-1.175)   0.714           74.8%               \<0.001
  **Immune checkpoint molecules**                                                                                                                              
  PD-L1                                        32              4854            0.874 (0.711-1.073)   0.197                 72.8%           \<0.001             
  PD-1                                         7               967             0.926 (0.424-2.025)   0.848                 76.7%           \<0.001             
  IDO                                          4               404             2.197 (1.199-4.023)   0.011                 59.8%           0.059               
  **Ethnicity**                                                                                                                                                
  Asian                                        19              2938            0.923 (0.651-1.307)   0.650                 77.1%           \<0.001             
  Caucasian                                    24              3287            0.995 (0.779-1.270)   0.965                 73.8%           \<0.001             
  **Tumor location**                                                                                                                                           
  OSCC                                         13              1477            0.879 (0.586-1.317)   0.532                 85.0%           \<0.001             
  NPC                                          10              1008            0.862 (0.618-1.203)   0.383                 33.7%           0.139               
  OPSCC                                        4               592             0.878 (0.532-1.450)   0.611                 47.1%           0.129               
  HPSCC                                        1               83              1.300 (0.700-2.415)   0.407                 \-              \-                  
  SSCC                                         1               53              1.355 (0.739-2.485)   0.326                 \-              \-                  
  LSCC                                         2               447             1.517 (0.252-9.126)   0.649                 91.4%           0.001               
  **Sample size**                                                                                                                                              
  Large                                        14              3721            1.044 (0.803-1.356)   0.748                 74.0%           \<0.001             
  Small                                        29              2504            0.915 (0.687-1.220)   0.546                 74.3%           \<0.001             
  DFS                                          Overall         19              2901                  1.097 (0.733-1.642)   0.652           92.5%               \<0.001
  **Inhibitory immune checkpoint molecules**                                                                                                                   
  PD-L1                                        13              2010            0.874 (0.523-1.459)   0.606                 94.1%           \<0.001             
  IDO                                          2               258             1.725 (0.611-4.869)   0.303                 59.5%           0.116               
  PD-1                                         4               633             1.931 (0.716-5.211)   0.194                 87.5%           \<0.001             
  **Ethnicity**                                                                                                                                                
  Asian                                        8               1252            1.131 (0.506-2.533)   0.764                 93.6%           \<0.001             
  Caucasian                                    11              1649            1.060 (0.760-1.479)   0.731                 73.9%           \<0.001             
  **Tumor location**                                                                                                                                           
  OSCC                                         3               247             0.609 (0.208-1.788)   0.367                 70.8%           0.033               
  NPC                                          6               666             1.339 (0.581-3.085)   0.494                 92.5%           \<0.001             
  SSCC                                         1               53              1.834 (0.955-3.522)   0.068                 \-              \-                  
  OPSCC                                        1               181             1.090 (0.783-1.518)   0.610                 \-              \-                  
  LSCC                                         2               447             1.282 (0.242-6.783)   0.770                 85.9%           0.008               
  **Sample size**                                                                                                                                              
  Large                                        6               1756            0.844 (0.595-1.198)   0.343                 75.5%           \<0.001             
  Small                                        13              1145            1.225 (0.764-1.963)   0.399                 88.9%           \<0.001             
  PFS                                          Overall         6               545                   0.996 (0.585-1.685)   0.989           68.5%               0.007
  **Inhibitory immune checkpoint molecules**                                                                                                                   
  PD-L1                                        6               545             0.891 (0.565-1.404)   0.989                 68.5%           0.007               
  **Ethnicity**                                                                                                                                                
  Asian                                        3               233             0.846 (0.492-1.455)   0.744                 48.3%           0.144               
  Caucasian                                    3               312             1.218 (0.372-3.993)   0.546                 82.7%           0.003               
  **Tumor location**                                                                                                                                           
  NPC                                          2               227             0.762 (0.506-1.149)   0.195                 0.0%            0.935               
  OSCC                                         1               84              0.576 (0.308-1.076)   0.084                 \-              \-                  
  HPSCC                                        1               83              1.350 (0.740-2.463)   0.328                 \-              \-                  
  **Sample size**                                                                                                                                              
  Large                                        1               161             0.770 (0.480-1.235)   0.279                 \-              \-                  
  Small                                        5               384             1.067 (0.536-2.125)   0.853                 73.0%           0.005               
  DSS                                          Overall         5               699                   0.779 (0.330-1.839)   0.569           84.7%               \<0.001
  DMFS                                         Overall         3               361                   0.599 (0.346-1.035)   0.066           0.0%                0.604
  -------------------------------------------- --------------- --------------- --------------------- --------------------- --------------- ------------------- ---------
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Subgroup analyses
-----------------

Subgroup analyses stratified according to the immune checkpoint molecule, patient ethnicity, tumor location and sample size were performed to detect potential sources of heterogeneity. In the stratification based on the immune checkpoint molecule ([Figure 2](#f2){ref-type="fig"}), poorer OS was consistently found in patients with higher levels of IDO ([Table 2](#t2){ref-type="table"}), correlating with a poorer prognosis (HR = 2.197, 95% CI: 1.199-4.023, *P* = 0.011, [Figure 2](#f2){ref-type="fig"}). However, no obvious trend in DFS was found according to IDO expression ([Table 2](#t2){ref-type="table"}).

The same hierarchical strategy was used to evaluate the studies of PD-L1 ([Table 3](#t3){ref-type="table"}). Among the immune checkpoint molecules, PD-L1 was the focus of the largest percentage of studies, as 32 studies with 4854 patients reported the relationship between PD-L1 expression and OS ([Figure 3](#f3){ref-type="fig"}). There was a possible trend for a better prognosis in patients overexpressing PD-L1 (HR = 0.874; 95% CI: 0.711-1.073, *P* = 0.197).

###### Results of the meta-analysis on the prognostic effects of PD-L1 in HNC patients.

  -------------------- --------------- --------------- --------------------- --------------------- --------------- ------------------- ---------
                       **Variable**    **Study no.**   **Sample size**       **HR (95% CI)**       ***P* value**   **Heterogeneity**   
  **I^2^**             ***P* value**                                                                                                   
  OS                   Overall         32              4854                  0.874 (0.711-1.073)   0.197           72.8%               \<0.001
  **Ethnicity**                                                                                                                        
  Asian                14              2074            0.792 (0.537-1.168)   0.240                 78%             \<0.001             
  Caucasian            18              2780            0.91 (0.716-1.158)    0.444                 68.2%           \<0.001             
  **Tumor location**                                                                                                                   
  OSCC                 10              1198            0.726 (0.470-1.121)   0.148                 84.7%           \<0.001             
  NPC                  7               795             0.692 (0.523-0.915)   0.01                  0.0%            0.855               
  OPSCC                3               495             0.975 (0.771-1.234)   0.835                 0.0%            0.403               
  HPSCC                1               83              1.300 (0.700-2.415)   0.407                 \-              \-                  
  SSCC                 1               53              1.355 (0.739-2.485)   0.326                 \-              \-                  
  LSCC                 1               260             0.635 (0.393-1.025)   0.063                 \-              \-                  
  **Sample size**                                                                                                                      
  Large                12              3132            1.022 (0.790-1.321)   0.87                  71.4%           \<0.001             
  Small                20              1722            0.77 (0.575-1.031)    0.08                  66.6%           \<0.001             
  DFS                  Overall         13              2011                  0.874 (0.523-1.465)   0.607           93.9%               \<0.001
  **Ethnicity**                                                                                                                        
  Asian                5               617             0.824 (0.290-2.338)   0.716                 94.2%           \<0.001             
  Caucasian            8               1394            0.883 (0.638-1.221)   0.451                 62.4%           0.009               
  **Tumor location**                                                                                                                   
  OSCC                 3               247             0.610 (0.208-1.793)   0.369                 70.5%           0.034               
  NPC                  4               549             1.042 (0.349-3.111)   0.941                 94.9%           \<0.001             
  SSCC                 1               53              1.834 (0.955-3.522)   0.068                 \-              \-                  
  OPSCC                1               181             1.090 (0.783-1.518)   0.610                 \-              \-                  
  LSCC                 1               260             0.591 (0.350-0.997)   0.048                 \-              \-                  
  **Sample size**                                                                                                                      
  Large                4               1167            0.829 (0.597-1.151)   0.263                 57.5%           0.07                
  Small                9               844             0.900 (0.454-1.785)   0.762                 91.7%           \<0.001             
  PFS                  Overall         7               630                   0.996 (0.632-1.569)   0.986           62.1%               0.015
  **Ethnicity**                                                                                                                        
  Asian                4               318             0.879 (0.585-1.321)   0.534                 24.2%           0.266               
  Caucasian            3               312             1.219 (0.372-3.997)   0.744                 82.6%           0.003               
  **Tumor location**                                                                                                                   
  OSCC                 2               169             0.706 (0.416-1.197)   0.196                 7.8%            0.298               
  HPSCC                1               83              1.350 (0.737-2.473)   0.331                 \-              \-                  
  NPC                  2               227             0.762 (0.503-1.154)   0.200                 0.0%            0.935               
  **Sample size**                                                                                                                      
  Large                1               161             0.770 (0.476-1.246)   0.287                 \-              \<0.001             
  Small                6               469             1.058 (0.600-1.876)   0.845                 66.2%           0.011               
  DSS                  Overall         5               699                   0.779 (0.330-1.839)   0.569           84.7%               \<0.001
  DMFS                 Overall         3               361                   0.599 (0.346-1.035)   0.066           0.0%                0.604
  -------------------- --------------- --------------- --------------------- --------------------- --------------- ------------------- ---------
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In nasopharyngeal carcinoma (NPC) patients, the OS was better for those expressing higher levels of PD-L1 (HR = 0.692, 95% CI: 0.523-0.915, *P* = 0.010). However, no obvious trend in DFS, PFS, DSS or DMFS was found according to PD-L1 expression. In laryngeal squamous cell carcinoma patients, higher PD-L1 expression was associated with better DFS (HR = 0.591, 95% CI: 0.350-0.997, *P* = 0.048).

Sensitivity analysis and publication bias
-----------------------------------------

A sensitivity analysis of the association between the expression of PD-L1 and the prognosis of HNC patients was performed for high-quality studies (NOS score ≥ 7, [Table 4](#t4){ref-type="table"}). The overall HRs and 95% CIs followed the same trends as those in the previous analysis. Higher levels of PD-L1 exhibited a trend of correlation with better OS (HR = 0.754, 95% CI: 0.568-1.002, *P* = 0.051, [Figure 4A](#f4){ref-type="fig"}) and were associated with better PFS (HR = 0.618, 95% CI: 0.388-0.985, *P* = 0.043, [Figure 4B](#f4){ref-type="fig"}) in the high-quality studies. As in the previous analysis, the OS of NPC patients was better in the high-PD-L1 group (HR = 0.649, 95% CI: 0.458-0.920, *P* = 0.015, [Figure 4A](#f4){ref-type="fig"}). The heterogeneity among the studies decreased slightly for OS, but it remained statistically significant (I^2^ = 76.6%, *P*~h~ \< 0.001; [Table 4](#t4){ref-type="table"}). In addition, subgroup analyses revealed that higher PD-L1 levels were associated with better OS in Caucasian patients (HR = 0.742, 95% CI: 0.578-0.954, *P* = 0.020) and in studies with small sample sizes (HR = 0.582, 95% CI: 0.426-0.796, *P* \< 0.001, [Table 4](#t4){ref-type="table"}).

###### Sensitivity analysis results for high-quality studies on the prognostic effects of PD-L1 in HNC patients.

  -------------------- --------------- --------------- --------------------- --------------------- --------------- ------------------- ---------
                       **Variable**    **Study no.**   **Sample size**       **HR (95% CI)**       ***P* value**   **Heterogeneity**   
  **I^2^**             ***P* value**                                                                                                   
  OS                   Overall         17              2581                  0.754 (0.568-1.002)   0.051           76.6%               \<0.001
  **Ethnicity**                                                                                                                        
  Asian                7               1255            0.720 (0.385-1.348)   0.305                 88.1%           \<0.001             
  Caucasian            10              1326            0.742 (0.578-0.954)   0.020                 46.1%           0.054               
  **Tumor location**                                                                                                                   
  OSCC                 5               531             0.653 (0.292-1.462)   0.300                 90.7%           \<0.001             
  NPC                  3               389             0.649 (0.458-0.920)   0.015                 0.0%            0.744               
  OPSCC                3               495             0.975 (0.771-1.234)   0.835                 0.0%            0.403               
  LSCC                 1               260             0.635 (0.393-1.025)   0.063                 \-              \-                  
  **Sample size**                                                                                                                      
  Large                7               1715            0.984 (0.659-1.468)   0.936                 79.5%           \<0.001             
  Small                10              866             0.582 (0.426-0.796)   0.001                 50.3%           0.034               
  DFS                  Overall         7               1066                  0.928 (0.618-1.392)   0.717           69.4%               0.003
  **Ethnicity**                                                                                                                        
  Asian                3               416             0.809 (0.241-2.720)   0.732                 85.8%           0.001               
  Caucasian            4               650             0.938 (0.663-1.328)   0.719                 43.6%           0.150               
  **Tumor location**                                                                                                                   
  OSCC                 2               148             0.699 (0.114-4.263)   0.697                 78.4%           0.032               
  NPC                  2               348             1.215 (0.288-5.133)   0.791                 91.0%           0.001               
  OPSCC                1               181             1.090 (0.783-1.518)   0.610                 \-              \-                  
  LSCC                 1               260             0.591 (0.351-0.996)   0.048                 \-              \-                  
  **Sample size**                                                                                                                      
  Large                3               650             0.753 (0.485-1.171)   0.208                 66.8%           0.049               
  Small                4               416             1.146 (0.536-2.450)   0.725                 71.0%           0.016               
  PFS                  Overall         3               188                   0.618 (0.388-0.985)   0.043           0.0%                0.867
  -------------------- --------------- --------------- --------------------- --------------------- --------------- ------------------- ---------

![**Overall forest plots of sensitivity analysis.** (**A**) Stratified analysis based on the tumor location for the association between PD-L1 and OS. (**B**) Overall forest plots of sensitivity analysis for the association between PD-L1 and PFS.](aging-11-101756-g004){#f4}

Funnel plots of OS were created for all the studies ([Figure 5A](#f5){ref-type="fig"}), for the studies on PD-L1 ([Figure 5B](#f5){ref-type="fig"}) and for the high-quality studies on PD-L1 ([Figure 5C](#f5){ref-type="fig"}). For all three plots, the studies were distributed uniformly around the axis, manifesting no obvious publication bias (*P* = 0.509, 0.876 and 0.868 for all the studies, the studies on PD-L1 and the high-quality studies on PD-L1, respectively).

![**Begg's funnel plots of publication bias on the relationships between immune checkpoint molecules and OS** in all studies (**A**), PD-L1-associated studies (**B**) and high-quality studies on PD-L1 (**C**).](aging-11-101756-g005){#f5}

DISCUSSION
==========

As immune checkpoint molecules could be involved in the immune surveillance of tumor development and progression and the clearance of tumors \[[@r11]\], anti-immune-checkpoint drugs such as pembrolizumab \[[@r3],[@r19]\], nivolumab \[[@r26],[@r27]\] and ipilimumab \[[@r28]\] have been approved to treat melanoma, non-small cell lung cancer, renal cell carcinoma, prostate cancer and HNC. Recent studies have examined how immune checkpoint molecules, especially PD-L1, influence the prognosis of cancer patients, and a large number of updated reports have been published in the past two years. However, no consensus has been reached on the effects of immune checkpoint molecules on the prognosis of HNC.

This meta-analysis on the prognostic value of immune checkpoint molecules included 52 studies with a total of 7127 patients. The expression of immune checkpoint molecules was found to be a controversial prognostic factor for the OS, DFS, PFS, DSS and DMFS of HNC patients. Although the current view is that immune checkpoint molecules may be important predictors of a poor prognosis in HNC \[[@r17]--[@r19],[@r22],[@r29]--[@r31]\], our subgroup analysis stratified according to the immune checkpoint molecule revealed that different molecules had different associations with the patient prognosis. Thus, our results require careful attention.

Higher IDO expression was associated with a poorer prognosis for HNC patients in our study. Similarly, high IDO expression has been reported to correlate with a poor prognosis in patients with melanoma, breast cancer and colon cancer \[[@r32]--[@r34]\]. However, in our study, higher expression of PD-L1 tended to be associated with better OS. Kogashiwa et al. \[[@r35]\] found that higher expression of PD-L1 was associated with a higher number of CD8+ tumor-infiltrating lymphocytes, leading to better OS for HNC patients. Balermapas et al. and Hanna et al. \[[@r36],[@r37]\] also reported higher levels of tumor-infiltrating lymphocytes in HNC patients expressing higher levels of PD-L1, which could explain the improved OS of these patients.

As PD-L1 attracted the most attention of the included immune checkpoint molecules, and a large number of updated studies reported the relationship between high levels of PD-L1 and the prognosis of HNC in 2017 and 2018, we considered it important to conduct a further meta-analysis solely on this molecule. We found that higher PD-L1 expression was associated with better OS in NPC patients, although for HNC overall there was only a positive trend, rather than a concrete link ([Figure 3](#f3){ref-type="fig"}). A sensitivity analysis revealed the same trends in OS. In addition, higher PD-L1 expression was found to correlate with better PFS. The results of the sensitivity analysis may be more dependable than the former results, as all the included studies were of high quality. Furthermore, the same relationship between PD-L1 expression and OS was confirmed in Caucasian subjects, NPC patients and studies with small sample sizes.

Tumors can develop adaptive immune resistance, which is one of the two mechanisms regulating tumor PD-L1 expression (the second being intrinsic immune resistance) \[[@r38]\]. While the intrinsic mechanism leads to PD-L1 expression after oncogenic mutation \[[@r39]\], the adaptive mechanism causes tumor cells to express PD-L1 after they have been stimulated by interferon gamma secreted by CD8+ T cells \[[@r40],[@r41]\]. Therefore, tumor-membranous PD-L1 levels could partly reflect the amount of tumor-infiltrating lymphocytes, especially cytotoxic T cells, accounting to some extent for the better survival of patients with higher PD-L1 levels.

There are several limitations to this meta-analysis. Firstly, the overall heterogeneity was high, so random effects models were required for the analysis, and there was less sensitivity to detect significant differences. Secondly, all the included studies were prospective, and the majority of studies did not have adequate random sequences or comparable cohorts, increasing the risk of bias. Thus, the quality of the included studies was not perfect. Lastly, the study populations were all of Asian or Caucasian ethnicity, which may have caused a population selection bias.

Our meta-analysis indicated that different immune checkpoint molecules correlated with different prognoses in HNC patients: higher IDO expression predicted a poorer prognosis, while higher PD-L1 expression was associated with a better prognosis. Furthermore, our study revealed that higher expression of PD-L1 was associated with significantly better OS in Caucasian subjects, NPC patients and studies with small sample sizes. In summary, our study suggested that the immune checkpoint molecules IDO and PD-L1 have potential prognostic value and applicability to immune therapy for HNC.

METHODS
=======

Literature-search strategy
--------------------------

This literature search was performed on August 10, 2018 without any restrictions in region, publication type, journal or language. The databases of PubMed, Embase and the Cochrane Library were thoroughly searched with the following strategy: ((((((((((((((((((((((((((head and neck cancer \[Title/Abstract\]) OR head and neck squamous cell carcinoma\[Title/Abstract\]) OR head and neck neoplasm\$\[Title/Abstract\]) OR HNSCC\[Title/Abstract\]) OR SCCHN\[Title/Abstract\]) OR HNC\[Title /Abstract\]) OR mouth neoplasms\[Title /Abstract\]) OR cancers of mouth\[Title/Abstract\]) OR oral\[Title/Abstract\]) OR laryn\*\[Title/Abstract\]) OR pharyn\*\[Title/Abstract\]) OR tongue\[Title/Abstract\]) OR oropharyn\*\[Title/Abstract\]) OR nasopharyn\*\[Title/Abstract\]) OR hypopharyn\*\[Title/Abstract\]) OR trachea\[Title/Abstract\]) OR laryngopharyn\*\[Title /Abstract\]) OR cervical tracheal\[Title/Abstract\]) OR cervical esophagus\[Title/Abstract\]) OR lip\[Title /Abstract\])) OR sinonasal\[Title/Abstract\]) OR head and neck cutaneous squamous cell carcinoma\[Title/Abstract\]) OR squamous cell carcinoma of the oral cavity\[Title/Abstract\]) OR salivary gland carcinoma\[Title/Abstract\]) OR SGC\[Title/Abstract\]) AND (((((((((((((((((((((((((b7-h3\[Title/Abstract\]) OR cd276\[Title/Abstract\]) OR b7-h4\[Title/Abstract\]) OR vtcn1\[Title/Abstract\]) OR btla\[Title/Abstract\]) OR b and t lymphocyte attenuator) OR cd272\[Title/Abstract\]) OR ctla-4\[Title/Abstract\]) OR cytotoxic t-lymphocyte-associated protein 4\[Title/Abstract\]) OR cd152\[Title /Abstract\]) OR ido\[Title/Abstract\]) OR indoleamine 2,3-dioxygenase\[Title/Abstract\]) OR kir\[Title/Abstract\]) OR killer-cell immunoglobulin-like receptor\[Title/Abstract\]) OR lag3\[Title/Abstract\]) OR lymphocyte activation gene-3\[Title/Abstract\]) OR pd-1\[Title/Abstract\]) OR programmed death 1 receptor\[Title/Abstract\]) OR pd-l1\[Title/Abstract\]) OR programmed death ligand 1\[Title/Abstract\]) OR pd-l2\[Title/Abstract\]) OR tim-3\[Title/Abstract\]) OR t-cell immunoglobulin domain and mucin domain 3\[Title/Abstract\]) OR vista\[Title/Abstract\]) OR v-domain ig suppressor of t cell activation\[Title/Abstract\]) OR b7-h1\[Title/Abstract\]). Two reviewers (Y.Q.J. and B.Y.) inspected all candidate articles independently. Discrepancies were resolved by discussion with the senior authors (Z.W. and B.C.).

Inclusion and exclusion criteria
--------------------------------

The available prospective comparative studies (cohort studies) were included in this study based on their conformance to the following inclusion criteria: 1) the association of immune checkpoint marker expression with OS/DFS/PFS/DSS/DMFS in HNC was reported; 2) the diagnosis of HNC was made based on pathological examination; 3) HRs and 95% CIs were provided or could be estimated from the text; 4) only the more recent or complete article was selected when multiple reports described the same population, to avoid the duplicate inclusion of data; and 5) articles were published as original research.

The exclusion criteria were: 1) reviews, meeting abstracts, letters; 2) animal model studies; 3) sample size \< 30 patients; 4) insufficient data to estimate the HR and 95% CI; 5) the main type of tumor was not SCC; 6) the number of studies on a single molecule was less than three; and 7) the study design was not prospective.

Data extraction and quality assessment
--------------------------------------

Two reviewers (Y.Q.J. and B.Y.) extracted the following information independently from the included studies: author, year of publication, study country or region, sample ethnicity, tumor location, follow-up period, sample size, gender, cut-off values of immune checkpoint molecules, detection method, TNM stage, and survival data such as OS, DFS, PFS, DSS and DMFS. The HR and 95% CI were either reported or calculated from the *P* value or Kaplan-Meier survival curve \[[@r42],[@r43]\]. Disagreements were resolved by a senior reviewer (Z.W.).

Two reviewers (L.L.W. and W.X.M.) independently assessed the quality of the included studies by the NOS. A score of 0--9 was given to each study, and studies with NOS scores ≥ 7 were defined as high-quality. Consensus was reached by discussion with senior reviewers (B.C. and Z.W.) when there were inconsistent results. Importantly, the procedure of assessing the quality of the studies was blinded to the reviewers who extracted the data (Y.Q.J. and B.Y.).

Statistical analysis
--------------------

This meta-analysis was performed in accordance with recommendations from the Cochrane Collaboration and the Quality of Reporting of Meta-analyses guidelines \[[@r44],[@r45]\]. The HR was used as a summary statistic for censored outcomes (OS, DFS, PFS, DSS and DMFS). HRs \> 1 represented a poor prognosis in HNC.

Heterogeneity among the primary studies was evaluated by Cochrane's Q statistic and the I^2^ statistic. A *P* value \< 0.10 in Cochrane's Q test or an I^2^ value \> 50% indicates substantial heterogeneity among studies, so a random effects model was used to calculate the pooled HR and 95% CI in such cases. Otherwise, a fixed effects model was applied.

We used the mean sample size as the boundary between studies with large and small sample sizes. Subgroup analyses were carried out according to the immune checkpoint molecule, ethnicity, sample size and tumor location. Sensitivity analysis was applied to high-quality studies (NOS ≥ 7). Begg's funnel plots were used to assess publication bias. All statistical analyses were conducted with STATA 12.0 statistical software (Stata Corporation, College Station, TX, USA). A two-tailed *P* value \< 0.05 was considered statistically significant.
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